George Par, MD
Retina Specialist · Las Vegas, NVNPI 1922325448
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $88,900 of the $110,296 with a category attached, or 80.6%. Novartis accounts for 90.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $102,735 and has fallen 99.5% since, to $493 in 2025.
Across 146 payments — averaging $755.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$99K
- Alimera Sciences, Inc.$8K
- Regeneron Healthcare Solutions, Inc.$837
- US Retina LLC$674
- Genentech USA, Inc.$634
- Biogen$219
- plus $860 from 10 others
What the payments were for
- Speaking & faculty fees$88,90081%
- Travel & lodging$16,34415%
- Food & beverage$4,3374%
- Education$410%
- Ownership interest$6741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 68 | $99,230 |
| Alimera Sciences, Inc. | 10 | $7,842 |
| Regeneron Healthcare Solutions, Inc. | 17 | $837 |
| US Retina LLC | 2 | $674 |
| Genentech USA, Inc. | 21 | $634 |
| Biogen | 4 | $219 |
| Apellis Pharmaceuticals, Inc. | 2 | $154 |
| AbbVie(2 entities) | 7 | $135 |
| Amgen | 1 | $122 |
| Genentech, Inc. | 3 | $121 |
| Astellas Pharma US Inc | 6 | $121 |
| Astellas Pharma Global Development | 1 | $70 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Harrow Eye, LLC | 1 | $27 |
| Sandoz | 1 | $25 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few retina specialist providers in Nevadato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 129 | $7,087 |
| MoxifloxacinMoxifloxacin Hcl | 44 | $1,166 |
| Latanoprost | 63 | $707 |
| Brimonidine Tartrate | 56 | $426 |
| Timolol Maleate | 52 | $340 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 30 | $291 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $255 |
| Dorzolamide Hcl | 12 | $139 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 14 | $97 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Las Vegas
- Chris WuLas Vegas$11K
- Russell JayneLas Vegas$8K
- Charles CalvoLas Vegas$2K
- Alec AmramLas Vegas$1K
- Tyson WardLas Vegas$1K
- Greggory GahnReno$15K
- Spencer FullerReno$6K
- William StevensonReno$5K
- John GunnHenderson$1K
- Zachary BodnarHenderson$724
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.